Living cell therapy for the treatment of diabetic foot ulcers
from Podiatry Management
In the year 2000, Apligraf was cleared by the FDA for use on diabetic foot ulcers. One year later, Dermagraft was also approved, signaling the start of a new approach for the treatment of diabetic foot ulcers. Both of these products contain living cells, which have been prepared for application to the wound of a recipient. Apligraf contains both human keratinocytes and fibroblasts attached to a bovine collagen matrix, while Dermagraft contains human fibroblasts attached to an absorbable polyglactin absorbable mesh substrate. Aside from a few more uncommon biologic products, living cell therapy was previously only available through the use of a split thickness or full thickness autograft.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063